查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1965798

兽医肿瘤市场－全球产业规模、份额、趋势、机会、预测：按动物类型、治疗类型、癌症类型、地区和竞争格局划分，2021-2031年

Veterinary Oncology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Animal Type, By Treatment Type, By Cancer Type, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球兽医肿瘤市场预计将从 2025 年的 18.2 亿美元增长到 2031 年的 36.2 亿美元，复合年增长率达 12.14%，实现了显着增长。

该市场涵盖了伴侣动物癌症管理的广泛解决方案，包括诊断工具、外科手术以及化疗和免疫疗法等治疗药物。推动这一市场扩张的关键因素是老年宠物肿瘤疾病发生率的上升，以及由于人类与动物之间日益紧密的联繫，饲主对专业医疗服务的需求不断增长。此外，宠物保险产业的快速发展也提供了重要的资金支持。根据北美宠物健康保险协会 (NAPHIA) 统计，2024 年北美地区的宠物保险保费总额将达到 52 亿美元。这些资金支持使得以往费用高昂的复杂肿瘤治疗对宠物饲主来说更加经济实惠。

市场概览
预测期 2027-2031
市场规模：2025年 18.2亿美元
市场规模：2031年 36.2亿美元
复合年增长率：2026-2031年 12.14%
成长最快的细分市场 放射治疗
最大的市场 北美洲

儘管前景乐观，但高昂的治疗费用仍是一大障碍，常常阻碍饲主主人制定长期治疗方案。全球范围内兽医肿瘤专科医生短缺，进一步加剧了这一经济障碍。这种短缺限制了许多地区提供的专业服务，可能阻碍整体市场成长。因此，儘管需求不断增长，但资金限制和专家短缺共同构成了兽医肿瘤服务推广和扩展的挑战。

市场驱动因素

伴侣动物癌症发生率的上升是全球兽医肿瘤市场的主要驱动力。随着宠物寿命因整体照护水准的提高而延长，肿瘤疾病的发生率自然也随之上升，从而增加了对更频繁、更先进的肿瘤治疗的需求。近期流行病学数据也印证了这个趋势。 2024年4月发表于PLOS One的一项研究估计，犬类肿瘤的发生率为每年每10万隻高危险犬775例，其中皮肤肿瘤占比最高，达34.64%。患者数量的增加得益于饲主医疗投入资金。根据美国宠物用品协会统计，截至2024年3月，美国兽医保健及相关产品的年销售额已达383亿美元，显示强劲的经济基础支撑着这些重要服务的广泛普及。

同时，新型标靶治疗和免疫疗法的研发正在改变临床实践，并将市场格局从传统化疗转向精准医疗。製药和生物技术公司正积极利用人工智慧（AI）和基因组分析来设计个人化治疗方案，以提高疗效并最大限度地减少副作用。这项技术变革的影响在近期的临床结果中显而易见。根据Imprimed于2024年3月发布的报告，采用AI预测通讯协定治疗高级别T细胞淋巴瘤犬的缓解率达到了59%，显着高于低匹配组的9.1%。这些进展不仅提高了存活率，也展现了先进肿瘤解决方案的商业性潜力，并鼓励企业持续加强研发投入。

市场挑战

治疗费用不断上涨是全球兽医肿瘤市场扩张的主要障碍。先进的癌症治疗（包括诊断、特殊手术、长期化疗等）费用高昂，往往超出许多宠物饲主的经济承受能力。这种经济差距常常迫使宠物主人放弃建议的肿瘤治疗方案，转而选择费用较低的安宁疗护或安乐死。这些经济限制直接减少了复杂手术的数量，抑制了依赖先进疗法广泛应用的专业兽医中心和药物供应商的收入成长。

这种对成本的敏感度也体现在近期产业数据中，数据显示消费者在动物保健方面的支出有所下降，尤其对高成本专科领域的影响更为显着。根据美国兽医协会（AVMA）预测，2024年兽医总支出将年上年度4%。这主要是由于宠物饲主预算紧张所致。由于经济可行性仍然是饲主决策的首要因素，因此这种支出能力的下降限制了昂贵肿瘤治疗的潜在市场规模。因此，对于相当一部分宠物主人而言，价格高昂的有效癌症治疗仍然难以负担，从而限制了市场的成长潜力。

市场趋势

液态生物检体和非侵入性诊断检测的出现，正彻底改变肿瘤疾病的检测方式，使其从侵入性组织取样转向基于血液的生物标记筛检。这种诊断方法使兽医能够在疾病早期识别循环肿瘤DNA和核小体，从而显着提高预后和监测能力，且无需承担切片检查的风险。随着这些便利的筛检工具被纳入老年宠物的常规健康检查，其商业性应用正在加速发展。例如，VolitionRx公司报告称，仅在2024年12月的第三季度，其Nu.Q Vet癌症筛检试剂盒的销量就达到了约5万份，这凸显了市场对可靠的非侵入性诊断解决方案的强劲需求。

同时，立体定位和移动放射治疗技术的进步正在改变治疗通讯协定，使高剂量辐射能够以亚毫米级的精度进行传输。与需要在数週内进行多次麻醉的传统分次放射治疗不同，立体定位放射放射线手术(SRS) 和立体定位局部放射治疗 (SBRT) 通常只需一到三次疗程即可完成治疗，从而减轻患者的压力和麻醉相关的风险。这项技术进步扩大了可治疗的患者群体，包括以前被认为无法切除或对传统治疗方法过于脆弱的病例。正如 Thrive Pet Healthcare 在 2024 年 4 月宣布的那样，其专业合作伙伴 PetCure Oncology 已为超过 8,000 隻宠物实施了这些先进的放射线治疗，取得了重要的临床里程碑，凸显了人们对精准高效治疗方法的日益依赖。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球兽医肿瘤市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 动物种类（狗、猫、其他）
    • 治疗方法（放射线治疗、手术、化疗、其他）
    • 癌症类型（皮肤癌、淋巴瘤、肉瘤、其他）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美兽医肿瘤市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲兽医肿瘤市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区兽医肿瘤市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲兽医肿瘤市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲兽医肿瘤市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球兽医肿瘤市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Elanco Animal Health Incorporated
  • Boehringer Ingelheim International GmbH
  • Zoetis Inc.
  • Elekta AB
  • PetCure Oncology
  • Accuray Incorporated
  • Varian Medical Systems, Inc.
  • Virbac SA
  • Merck & Co., Inc.
  • Dechra Pharmaceuticals PLC
  • NovaVive Inc.
  • Ardent Animal Health, LLC

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 27376

The Global Veterinary Oncology Market is projected to experience substantial growth, expanding from USD 1.82 Billion in 2025 to USD 3.62 Billion by 2031, reflecting a compound annual growth rate of 12.14%. This market covers a wide spectrum of cancer management solutions for companion animals, including diagnostic tools, surgical interventions, and therapeutic agents such as chemotherapy and immunotherapy. The primary drivers of this expansion are the increasing incidence of neoplastic diseases among aging pet populations and the strengthening bond between humans and animals, which encourages owners to seek specialized medical care. Additionally, the rapid growth of the pet insurance sector serves as a crucial financial enabler; the North American Pet Health Insurance Association reported that total premium volume in North America reached $5.2 billion in 2024. This financial support makes complex oncological procedures more affordable for pet owners who previously found them cost-prohibitive.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 1.82 Billion
Market Size 2031USD 3.62 Billion
CAGR 2026-203112.14%
Fastest Growing SegmentRadiotherapy
Largest MarketNorth America

Despite this positive outlook, the market encounters significant obstacles due to high treatment costs, which frequently deter owners from committing to long-term care plans. This economic barrier is further complicated by a global shortage of board-certified veterinary oncologists. This scarcity limits the availability of specialized services in many geographic regions, potentially restricting broader market growth. Consequently, while demand is rising, the combination of financial constraints and a limited specialist workforce presents a challenge to the widespread accessibility and expansion of veterinary oncology services.

Market Driver

The escalating prevalence of cancer in companion animals acts as the primary catalyst for the Global Veterinary Oncology Market. As improvements in general care extend pet lifespans, the incidence of neoplastic diseases has naturally increased, creating a greater need for frequent and sophisticated oncological interventions. This trend is substantiated by recent epidemiological data; a study published in PLOS One in April 2024 calculated the overall tumor incidence rate in dogs at 775 per 100,000 dog-years at risk, with skin tumors constituting the largest category at 34.64% of cases. This rising patient volume is supported by an increase in owner spending power and a willingness to invest in medical outcomes. According to the American Pet Products Association, annual U.S. veterinary care and product sales hit $38.3 billion in March 2024, demonstrating a strong financial ecosystem that facilitates the adoption of these critical services.

Simultaneously, the development of novel targeted therapies and immunotherapies is transforming the clinical landscape, shifting the market focus from traditional chemotherapy toward precision medicine. Pharmaceutical and biotech companies are increasingly utilizing artificial intelligence and genomic profiling to design tailored treatment regimens that offer improved efficacy with fewer side effects. The impact of this technological shift is evident in recent clinical results; according to ImpriMed in March 2024, dogs with high-grade T-cell lymphoma treated with AI-predicted protocols achieved a remission rate of 59%, significantly surpassing the 9.1% remission rate seen in the low-matching group. These advancements not only enhance survival rates but also validate the commercial potential of sophisticated oncological solutions, encouraging continued investment in research and development.

Market Challenge

Prohibitive treatment expenses constitute a major barrier to the expansion of the Global Veterinary Oncology Market. The high costs associated with advanced cancer care, spanning diagnostics, specialized surgeries, and long-term chemotherapy, often exceed the financial means of many pet owners. This economic gap frequently forces clients to decline recommended oncological interventions in favor of less expensive palliative options or euthanasia. Such financial limitations directly reduce the volume of complex procedures performed, thereby suppressing revenue growth for specialized veterinary centers and pharmaceutical suppliers that depend on the widespread adoption of these advanced therapies.

This sensitivity to cost is mirrored in recent industry data showing a contraction in consumer spending on animal healthcare, which disproportionately impacts high-cost specialties. According to the American Veterinary Medical Association, overall veterinary spending dropped by 4% in 2024 compared to the previous year as pet owners faced tighter budgets. This reduction in spending capacity limits the addressable market for expensive oncology treatments, as financial feasibility remains a primary decision-making factor for clients. Consequently, the market faces capped growth potential, as the high price point of effective cancer management renders it inaccessible to a significant segment of the pet-owning population.

Market Trends

The emergence of liquid biopsy and non-invasive diagnostic testing is revolutionizing the detection of neoplastic diseases by moving away from invasive tissue sampling toward blood-based biomarker screening. This diagnostic method enables veterinarians to identify circulating tumor DNA or nucleosomes at earlier stages of disease, significantly enhancing prognostic accuracy and monitoring capabilities without the risks associated with surgical biopsies. The commercial adoption of these accessible screening tools is accelerating as they become integrated into routine wellness exams for aging pets. For example, VolitionRx reported in December 2024 that it sold approximately 50,000 units of its Nu.Q Vet Cancer Screening Test in the third quarter alone, highlighting the robust market demand for reliable, non-invasive diagnostic solutions.

concurrently, advancements in stereotactic and mobile radiation therapy technologies are reshaping treatment protocols by allowing for the delivery of high-dose radiation with sub-millimeter precision. Unlike traditional fractionated radiotherapy that requires numerous anesthetic events over several weeks, stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) typically condense treatment into just one to three sessions, reducing patient stress and anesthesia-related risks. This technological evolution expands the treatable patient base to include cases previously considered unresectable or too medically fragile for conventional courses. According to Thrive Pet Healthcare in April 2024, its specialty partner PetCure Oncology achieved a significant clinical milestone by administering these advanced radiation therapies to over 8,000 pets, validating the growing reliance on precise, high-efficiency therapeutic modalities.

Key Market Players

  • Elanco Animal Health Incorporated
  • Boehringer Ingelheim International GmbH
  • Zoetis Inc.
  • Elekta AB
  • PetCure Oncology
  • Accuray Incorporated
  • Varian Medical Systems, Inc.
  • Virbac S.A.
  • Merck & Co., Inc.
  • Dechra Pharmaceuticals PLC
  • NovaVive Inc.
  • Ardent Animal Health, LLC

Report Scope

In this report, the Global Veterinary Oncology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Veterinary Oncology Market, By Animal Type

  • Canine
  • Feline
  • Others

Veterinary Oncology Market, By Treatment Type

  • Radiotherapy
  • Surgery
  • Chemotherapy
  • Others

Veterinary Oncology Market, By Cancer Type

  • Skin Cancers
  • Lymphomas
  • Sarcomas
  • Others

Veterinary Oncology Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Veterinary Oncology Market.

Available Customizations:

Global Veterinary Oncology Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Veterinary Oncology Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Animal Type (Canine, Feline, Others)
    • 5.2.2. By Treatment Type (Radiotherapy, Surgery, Chemotherapy, Others)
    • 5.2.3. By Cancer Type (Skin Cancers, Lymphomas, Sarcomas, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Veterinary Oncology Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Animal Type
    • 6.2.2. By Treatment Type
    • 6.2.3. By Cancer Type
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Veterinary Oncology Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Animal Type
        • 6.3.1.2.2. By Treatment Type
        • 6.3.1.2.3. By Cancer Type
    • 6.3.2. Canada Veterinary Oncology Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Animal Type
        • 6.3.2.2.2. By Treatment Type
        • 6.3.2.2.3. By Cancer Type
    • 6.3.3. Mexico Veterinary Oncology Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Animal Type
        • 6.3.3.2.2. By Treatment Type
        • 6.3.3.2.3. By Cancer Type

7. Europe Veterinary Oncology Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Animal Type
    • 7.2.2. By Treatment Type
    • 7.2.3. By Cancer Type
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Veterinary Oncology Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Animal Type
        • 7.3.1.2.2. By Treatment Type
        • 7.3.1.2.3. By Cancer Type
    • 7.3.2. France Veterinary Oncology Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Animal Type
        • 7.3.2.2.2. By Treatment Type
        • 7.3.2.2.3. By Cancer Type
    • 7.3.3. United Kingdom Veterinary Oncology Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Animal Type
        • 7.3.3.2.2. By Treatment Type
        • 7.3.3.2.3. By Cancer Type
    • 7.3.4. Italy Veterinary Oncology Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Animal Type
        • 7.3.4.2.2. By Treatment Type
        • 7.3.4.2.3. By Cancer Type
    • 7.3.5. Spain Veterinary Oncology Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Animal Type
        • 7.3.5.2.2. By Treatment Type
        • 7.3.5.2.3. By Cancer Type

8. Asia Pacific Veterinary Oncology Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Animal Type
    • 8.2.2. By Treatment Type
    • 8.2.3. By Cancer Type
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Veterinary Oncology Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Animal Type
        • 8.3.1.2.2. By Treatment Type
        • 8.3.1.2.3. By Cancer Type
    • 8.3.2. India Veterinary Oncology Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Animal Type
        • 8.3.2.2.2. By Treatment Type
        • 8.3.2.2.3. By Cancer Type
    • 8.3.3. Japan Veterinary Oncology Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Animal Type
        • 8.3.3.2.2. By Treatment Type
        • 8.3.3.2.3. By Cancer Type
    • 8.3.4. South Korea Veterinary Oncology Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Animal Type
        • 8.3.4.2.2. By Treatment Type
        • 8.3.4.2.3. By Cancer Type
    • 8.3.5. Australia Veterinary Oncology Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Animal Type
        • 8.3.5.2.2. By Treatment Type
        • 8.3.5.2.3. By Cancer Type

9. Middle East & Africa Veterinary Oncology Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Animal Type
    • 9.2.2. By Treatment Type
    • 9.2.3. By Cancer Type
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Veterinary Oncology Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Animal Type
        • 9.3.1.2.2. By Treatment Type
        • 9.3.1.2.3. By Cancer Type
    • 9.3.2. UAE Veterinary Oncology Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Animal Type
        • 9.3.2.2.2. By Treatment Type
        • 9.3.2.2.3. By Cancer Type
    • 9.3.3. South Africa Veterinary Oncology Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Animal Type
        • 9.3.3.2.2. By Treatment Type
        • 9.3.3.2.3. By Cancer Type

10. South America Veterinary Oncology Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Animal Type
    • 10.2.2. By Treatment Type
    • 10.2.3. By Cancer Type
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Veterinary Oncology Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Animal Type
        • 10.3.1.2.2. By Treatment Type
        • 10.3.1.2.3. By Cancer Type
    • 10.3.2. Colombia Veterinary Oncology Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Animal Type
        • 10.3.2.2.2. By Treatment Type
        • 10.3.2.2.3. By Cancer Type
    • 10.3.3. Argentina Veterinary Oncology Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Animal Type
        • 10.3.3.2.2. By Treatment Type
        • 10.3.3.2.3. By Cancer Type

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Veterinary Oncology Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Elanco Animal Health Incorporated
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Boehringer Ingelheim International GmbH
  • 15.3. Zoetis Inc.
  • 15.4. Elekta AB
  • 15.5. PetCure Oncology
  • 15.6. Accuray Incorporated
  • 15.7. Varian Medical Systems, Inc.
  • 15.8. Virbac S.A.
  • 15.9. Merck & Co., Inc.
  • 15.10. Dechra Pharmaceuticals PLC
  • 15.11. NovaVive Inc.
  • 15.12. Ardent Animal Health, LLC

16. Strategic Recommendations

17. About Us & Disclaimer